COMMON STOCK PURCHASE AGREEMENTCommon Stock Purchase Agreement • March 19th, 2018 • Denali Therapeutics Inc. • Biological products, (no disgnostic substances) • Delaware
Contract Type FiledMarch 19th, 2018 Company Industry JurisdictionTHIS COMMON STOCK PURCHASE AGREEMENT (this “Agreement”), is made as of January 3, 2018 by and among Denali Therapeutics Inc., a Delaware corporation (the “Company”), and Takeda Pharmaceutical Company Limited, a corporation organized under the laws of Japan (the “Investor”).
OPTION AND COLLABORATION AGREEMENT between DENALI THERAPEUTICS INC. and TAKEDA PHARMACEUTICAL COMPANY LIMITEDOption and Collaboration Agreement • March 19th, 2018 • Denali Therapeutics Inc. • Biological products, (no disgnostic substances)
Contract Type FiledMarch 19th, 2018 Company IndustryThis Option and Collaboration Agreement (the “Agreement”) is made and entered into effective as of January 3, 2018 (the “Execution Date”) by and between Denali Therapeutics, Inc., a Delaware corporation (“Denali”), and Takeda Pharmaceutical Company Limited, a corporation organized under the laws of Japan (“Takeda”). Denali and Takeda are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
ConfidentialDevelopment and Manufacturing Services Agreement • March 19th, 2018 • Denali Therapeutics Inc. • Biological products, (no disgnostic substances)
Contract Type FiledMarch 19th, 2018 Company IndustrySPECIFIC TERMS IN THIS EXHIBIT HAVE BEEN REDACTED BECAUSE CONFIDENTIAL TREATMENT FOR THOSE TERMS HAS BEEN REQUESTED. THE REDACTED MATERIAL HAS BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION, AND THE TERMS HAVE BEEN MARKED AT THE APPROPRIATE PLACE WITH THREE ASTERISKS [***].
DENALI THERAPEUTICS INC. STANDSTILL AND STOCK RESTRICTION AGREEMENTStandstill and Stock Restriction Agreement • March 19th, 2018 • Denali Therapeutics Inc. • Biological products, (no disgnostic substances) • Delaware
Contract Type FiledMarch 19th, 2018 Company Industry JurisdictionThis Standstill and Stock Restriction Agreement (this “Agreement”) is made as of February 23, 2018 (“Effective Date”) by and among Denali Therapeutics Inc., a Delaware corporation (the “Company”) and Takeda Pharmaceutical Company Limited, a corporation organized under the laws of Japan (the “Investor”).